Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: A randomized, single-blind, 30-day trial

Clinical Therapeutics

Volumn 30, Issue 2, 2008, Pages 249-259

  Serebruany, Victor L ^a,b   Malinin, Alex I ^a   Pokov, Alex N ^a   Hanley, Daniel F ^b  

^a HeartDrug Research Laboratories   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ADENOSINE DIPHOSPHATE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CD14 ANTIGEN; CD31 ANTIGEN; CD40 LIGAND; CLOPIDOGREL; EPITOPE; GLITAZONE DERIVATIVE; GLYCOPROTEIN IB ALPHA; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; METFORMIN; PADGEM PROTEIN; PROTEINASE ACTIVATED RECEPTOR 1; SEROTONIN UPTAKE INHIBITOR; VITRONECTIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN ISCHEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; HEADACHE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; PATIENT COMPLIANCE; PILOT STUDY; PROPHYLAXIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; THROMBOCYTE AGGREGATION INHIBITION; TRANSIENT ISCHEMIC ATTACK; VOMITING;

ADULT; AGED; ASPIRIN; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; DIPYRIDAMOLE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; PILOT PROJECTS; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; SINGLE-BLIND METHOD; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 41549124477     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.02.006     Document Type: Article

References (33)

1. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
2. Hennekens C. Update on aspirin in treatment and prevention of cardiovascular disease. Am J Manag Care 8 Suppl 22 (2002) S691-S700
3. Diener H., Cunha L., Forbes C., et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 143 (1996) 1-13
4. Halkes P., van Gijn J., Kappelle L., et al., ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): Randomised controlled trial [published correction appears in Lancet. 2007;369:274]. Lancet 367 (2006) 1665-1673
5. The CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348 (1996) 1329-1339
6. Diener H., Bogousslavsky J., Brass L., et al., MATCH Investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebo-controlled trial. Lancet 364 (2004) 331-337
7. Standards of medical care in diabetes-2006. Diabetes Care 29 Suppl 1 (2006) S4-S42
8. Albers G., Caplan L., Easton J., et al., for the TIA Working Group. Transient ischemic attack-proposal for a new definition. N Engl J Med 347 (2002) 1713-1716
9. Breddin H. Can platelet aggregometry be standardized?. Platelets 16 (2005) 151-158
10. Hayward C., Harrison P., Cattaneo M., et al., Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 4 (2006) 312-319
11. Smith J., Steinhubl S., Lincoff A., et al. Rapid platelet-function assay: An automated and quantitative cartridge-based method. Circulation 99 (1999) 620-625
12. Ault K. Flow cytometric measurement of platelet function and reticulated platelets. Ann N Y Acad Sci 677 (1993) 293-308
13. Serebruany V., and Gurbel P. The relations of major platelet receptor expression during myocardial infarction. Monitoring efficacy of GPIIb/IIIa inhibitors by measuring P-selectin?. Thromb Haemost 81 (1999) 314-316
14. Lorenz R., Siess W., and Weber P. Effects of very low versus standard dose acetyl salicylic acid, dipyridamole and sulfinpyrazone on platelet function and thromboxane formation in man. Eur J Pharmacol 70 (1981) 511-518
15. Serebruany V., Malinin A., Sane D., et al. Magnitude and time course of platelet inhibition with Aggrenox and aspirin in patients after ischemic stroke: The AGgrenox versus Aspirin Therapy Evaluation (AGATE) Trial. Eur J Pharmacol 499 (2004) 315-324
16. Grau A., Reiners S., Lichy C., et al. Platelet function under aspirin, clopidogrel, and both after ischemic stroke: A case-crossover study. Stroke 34 (2003) 849-854
17. Serebruany V., Malinin A., Ziai W., et al. Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in patients after recent ischemic stroke. Stroke 36 (2005) 2289-2292 Plavix Use for Treatment of Stroke (PLUTO-Stroke) Trial.
18. Zhao L., Bath P., and Heptinstall S. Effects of combining three different antiplatelet agents on platelets and leukocytes in whole blood in vitro. Br J Pharmacol 134 (2001) 353-358
19. Zhao L., Fletcher S., Weaver C., et al. Effects of aspirin, clopidogrel and dipyridamole administered singly and in combination on platelet and leucocyte function in normal volunteers and patients with prior ischaemic stroke. Thromb Haemost 93 (2005) 527-534
20. Zhao L., Gray L., Leonardi-Bee J., et al. Effect of aspirin, clopidogrel and dipyridamole on soluble markers of vascular function in normal volunteers and patients with prior ischaemic stroke. Platelets 17 (2006) 100-104
21. Serebruany V., Malinin A., Oshrine B., et al. Lack of uniform platelet activation in patients after ischemic stroke and choice of antiplatelet therapy. Thromb Res 113 (2004) 197-204
22. Angiolillo D., Fernandez-Ortiz A., Bernardo E., et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 54 (2005) 2430-2435
23. Colwell J. Antiplatelet agents for the prevention of cardiovascular disease in diabetes mellitus. Am J Cardiovasc Drugs 4 (2004) 87-106
24. Roffi M., Moliterno D., Meier B., et al., TARGET Investigators. Impact of different platelet glycoprotein Ilb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up. Circulation 105 (2002) 2730-2736
25. Stuckey T., Stone G., Cox D., et al., CADILLAC Investigators. Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial). Am J Cardiol 95 (2005) 1-7
26. Akinboboye O., Idris O., Chou R., et al. Absolute quantitation of coronary steal induced by intravenous dipyridamole. J Am Coll Cardiol 37 (2001) 109-116
27. Eisert W. Near-field amplification of antithrombotic effects of dipyridamole through vessel wall cells. Neurology 57 Suppl 2 (2001) S20-S23
28. Iuliano L., Pedersen J., Rotilio G., et al. A potent chain-breaking antioxidant activity of the cardiovascular drug dipyridamole. Free Radic Biol Med 18 (1995) 239-247
29. Neri Serneri G., Masotti G., Poggesi L., et al. Enhanced prostacyclin production by dipyridamole in man. Eur J Clin Pharmacol 21 (1981) 9-15
30. Bult H., Fret H., Jordaens F., and Herman A. Dipyridamole potentiates the anti-aggregating and vasodilator activity of nitric oxide. Eur J Pharmacol 199 (1991) 1-8
31. Muller T. Inhibition of thrombus formation by low-dose acetylsalicylic acid, dipyridamole, and their combination in a model of platelet-vessel wall interaction. Neurology 57 Suppl 2 (2001) S8-S11
32. Singh J., Rothfuss K., Wiernicki T., et al. Dipyridamole directly inhibits vascular smooth muscle cell proliferation in vitro and in vivo: Implications in the treatment of restenosis after angioplasty. J Am Coll Cardiol 23 (1994) 665-671
33. Diener H., Sacco R., Yusuf S., and Steering Committee and the PRoFESS Study Group. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: The Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovasc Dis 23 (2007) 368-380